Connect with us

Technology

KROMATID Names Matthew Hemstreet CEO as Company Advances Toward Market Leadership in Cell & Gene Therapy

Published

on

BOULDER, Colo., June 18, 2026 /PRNewswire/ — KROMATID, a leader in structural genomic integrity analysis for the cell and gene therapy industry, today announced the appointment of Matthew Hemstreet as Chief Executive Officer, succeeding Interim CEO Terry Opgenorth.

KROMATID announces Matt Hemstreet as new CEO

Opgenorth was appointed Interim CEO during a pivotal period for the company and successfully guided KROMATID through a strategic transformation designed to strengthen its market position, sharpen its commercial focus, and establish a foundation for long-term growth. Under his leadership, KROMATID:

Refined brand positioning and market messaging to establish KROMATID as the leader in genomic integrity and single-cell analytics for cell and gene therapy.

Expanded and enhanced the genomic analysis portfolio to meet the evolving needs of pharmaceutical, biotechnology, and academic research organizations.

Developed a genomic intelligence platform leveraging KROMATID’s unique access to millions of chromosome images and deep expertise in structural abnormalities associated with gene editing technologies.

Strengthened operational discipline across commercialization, customer engagement, and product development functions.

“Terry was instrumental in helping position KROMATID for its next stage of growth,” said David Brunel, President of the Board of Directors. “His leadership strengthened our strategic direction, commercial execution, and organizational focus, leaving the company well-positioned for the future.”

With KROMATID’s strategic, technological, and commercial foundations firmly in place, the Board has appointed Matthew Hemstreet as Chief Executive Officer to lead the company’s next phase of expansion.

Since joining KROMATID as Vice President of Global Marketing in 2024, Hemstreet has played a key role in the company’s strategic and operational evolution. He brings more than a decade of leadership experience spanning global marketing, product management, and commercial strategy at Terumo Blood and Cell Technologies, Medtronic, Covidien, and others. Throughout his career, he has successfully launched more than 30 products and built high-performing teams focused on accelerating growth and delivering customer value.

“Matt combines deep cell therapy industry expertise with a proven ability to align strategy, execution, and innovation,” said Opgenorth. “He understands both the scientific and commercial opportunities ahead of us, and I am confident he is the right leader to guide KROMATID through its next chapter.”

As Chief Executive Officer, Hemstreet will focus on:

Expanding KROMATID’s presence within the global cell and gene therapy market.Strengthening strategic partnerships with pharmaceutical companies, biotechnology innovators, CDMOs, and academic research institutions.Accelerating adoption of the company’s KROMASURE™ platform and advancing new product innovations.Building the industry standard for genomic integrity assessment in advanced cellular therapies.

“I am honored to step into this role,” said Hemstreet. “The demand for deeper genomic integrity insights has never been greater. KROMATID is uniquely positioned to help developers of advanced therapies better understand, characterize, and de-risk their products. Our focus moving forward is clear: scale our impact, expand our capabilities, and establish genomic integrity as a foundational quality metric across the industry.”

The Board of Directors extends its gratitude to Terry Opgenorth for his leadership and contributions as Interim CEO; Opgenorth will continue to serve as a valued member of the board of directors and looks forward to supporting Hemstreet as he leads KROMATID into its next phase of growth and innovation.

About KROMATID

KROMATID is the leader in genomic structural analysis for cell and gene therapy developers, providing unparalleled clarity into chromosomal integrity. By combining proprietary imaging with advanced bioinformatics, KROMATID enables precise detection of structural variation and empowers developers to confidently advance therapies from discovery through regulatory approval. Learn more at www.kromatid.com

Media Contact

Amanda Ladas
Associate Director of Global Marketing
KROMATID
aladas@kromatid.com
773-720-0709

View original content to download multimedia:https://www.prnewswire.com/news-releases/kromatid-names-matthew-hemstreet-ceo-as-company-advances-toward-market-leadership-in-cell–gene-therapy-302803617.html

SOURCE KROMATID

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Infineon wins patent infringement case against Innoscience

Published

on

By

MUNICH, June 18, 2026 /PRNewswire/ — The District Court Munich, Germany (Landgericht München I) today ruled in favor of Infineon Technologies in two further of the patent infringement cases – specifically one based on a patent one based on a utility model – concerning gallium nitride (GaN) technology between Infineon and Innoscience.

The cases concern the unauthorized use of GaN technologies patented by Infineon by the Chinese company Innoscience. With today’s rulings, the court prohibits Innoscience from manufacturing, selling, and marketing additional patent-infringing products in Germany. Furthermore, the court has ordered Innoscience to pay damages to Infineon.

This marks Innoscience’s third and fourth legal defeat in a series of court cases, each of which found that Innoscience’s products infringe Infineon’s patents. Courts and authorities in both Germany and the United States have repeatedly concluded that Innoscience’s products infringe Infineon’s intellectual property rights. Prior rulings include the decision against Innoscience from August 1, 2025, in an initial German proceeding. Furthermore, on May 7, the Full Commission of the U.S. International Trade Commission (ITC) found that Innoscience had infringed an Infineon patent in the field of gallium nitride (GaN) technology. Additional proceedings regarding the infringement of other Infineon patents are pending in the U.S. and Germany.

GaN plays a pivotal role in enabling high-performance and energy-efficient power systems in a broad range of applications, including renewable energy systems, data centers, industrial automation, and electric vehicles (EVs).

“Today’s ruling demonstrates the value of our GaN portfolio and underscores our commitment to vigorously defending our intellectual property and promoting fair competition,” said Johannes Schoiswohl, Senior Vice President and Head of Infineon’s GaN Systems Business Line.

Infineon continuously strengthens its position as a leading integrated device manufacturer (IDM) in the GaN market with the industry’s broadest IP portfolio, comprising approximately 450 GaN patent families. The company remains dedicated to fostering innovation and advancing semiconductor technology to address the world’s most pressing challenges, from decarbonization to digital transformation.

About Infineon
Infineon Technologies AG is a global semiconductor leader in power systems and IoT. Infineon drives decarbonization and digitalization with its products and solutions. The Company had around 57,000 employees worldwide (end of September 2025) and generated revenue of about €14.7 billion in the 2025 fiscal year (ending 30 September). Infineon is listed on the Frankfurt Stock Exchange (ticker symbol: IFX) and in the USA on the OTCQX International over-the-counter market (ticker symbol: IFNNY).

Further information is available at www.infineon.com
This press release is available online at www.infineon.com/press
Follow us: Facebook – LinkedIn

Contact:
Andre Tauber,
andre.tauber@infineon.com,
Tel. +49 89 343 6705

View original content:https://www.prnewswire.co.uk/news-releases/infineon-wins-patent-infringement-case-against-innoscience-302804725.html

Continue Reading

Technology

The Inner Circle acknowledges Alan R. Mann as a Pinnacle Professional Member Inner Circle of Excellence

Published

on

By

MOORESVILLE, N.C., June 18, 2026 /PRNewswire/ — Prominently featured in The Inner Circle, Alan R. Mann is recognized as a Pinnacle Professional Member Inner Circle of Excellence for his contributions to Data Analytics and Decision Support.

Alan R. Mann has built a distinguished career in data analytics defined by precision, innovation, and a steadfast commitment to data integrity. With 36 years of experience spanning government, private sector, and health care environments, he is widely respected for transforming complex data into actionable insight that supports informed decision making and improved outcomes.

Since 2023, Mr. Mann has served as a data analyst and senior decision support analyst at Highmark Health, where he manages reporting package responsibilities for the Encompass team. In this role, he develops advanced programming that enables sales teams to deliver data driven client presentations, compare client profiles across multiple health care benefit metrics, and measure outcomes for up to nine chronic conditions.

Mr. Mann’s responsibilities also include evaluating additional coverage measurements and product performance metrics, conducting data discovery to integrate internal database sources, and reducing manual transcription through streamlined data workflows. He finalizes data integration efforts that improve reporting efficiency and supports enhancements to pharmacy focused reporting products, ensuring accuracy and consistency across all deliverables.

A critical component of his work involves designing comprehensive test plans to validate the accuracy and reliability of program outputs. When discrepancies or uncertainties arise, Mr. Mann rigorously retests and validates results, reinforcing his commitment to quality, precision, and trustworthy analytics. His expertise across government, health care, data science, and business analytics continues to add measurable value to the organizations he supports.

Mr. Mann earned a Bachelor of Arts degree from the University of Delaware and a Master of Science degree from Capella University. He further expanded his technical skill set through certification in artificial intelligence from the Texas McCombs School of Business. His professional affiliations include SAS, SASUG, Scouting America, and AEPhi, reflecting both his technical engagement and community involvement.

Outside of his professional work, Mr. Mann enjoys traveling, collecting model and toy trains, and playing guitar. He credits much of his success to the guidance of his mentor, Barry Morstan, and expresses deep gratitude to his wife, Louis, and his parents, Gilbert and Muriel, for their continued love and support.

Looking ahead, Mr. Mann plans to continue contributing to his organization while gradually preparing for the next phase of his professional journey, confident in the lasting impact of his work in data analytics and decision support.

Contact: Katherine Green, 516-825-5634, editorialteam@continentalwhoswho.com

View original content:https://www.prnewswire.com/news-releases/the-inner-circle-acknowledges-alan-r-mann-as-a-pinnacle-professional-member-inner-circle-of-excellence-302804593.html

SOURCE The Inner Circle

Continue Reading

Technology

Aquarius.io Launches Press AI & PR Spotlight: Your New AI Team

Published

on

By

They Call it “The Unfair Advantage”.

LOS ANGELES, Jun 18, 2026 /PRNewswire/ — 

Talent is not enough without a team.

Most people do not lose because they lack talent. They lose because they do not have a team behind them. Aquarius is out to change that. Two new tools, Press AI and PR Spotlight, put a full news team and a full marketing department in one person’s hands. It is the kind of firepower everyone needs go scale. See it all at Aquarius.io.

Press AI: a full news team for one person

Press AI is a full news team for one person. Give it a story and it researches live sources, checks the facts, turns your interviews into clean, quotable transcripts, and hands back a finished piece with sources attached, ready to file. It does the work of an entire team, so one reporter can chase more leads, break more stories, and beat every deadline.

“Talent is everywhere. The team behind it is not,” said Chaela Harrell, a co-founder of Aquarius. “Aquarius gives one person the power of a whole company. We are your unfair advantage.”

PR Spotlight: your own marketing department

PR Spotlight is a full marketing department in a single tool. Answer a few questions and it researches your brand, then builds investor grade pitch decks and complete media kits, designs your logo, and even handles your contracts, letting you upload, send, sign, and receive them through DocuSign. Together, Press AI and PR Spotlight do the work of an entire team, putting serious media and marketing power in anyone’s hands. Press AI and PR Spotlight are available now at Aquarius.io. Take a look, test it and see what the hype is about. 

The rest of the Aquarius family

Press AI and PR Spotlight join a whole family of Aquarius tools: Muse Lab for image and video, Chronicles for cinematic storytelling, Viral AI for social content, and Aria, a voice driven executive assistant. The platform is self serve, so you only pay for what you make. Every tool is built on one idea: give one person the team they never had. That is your unfair advantage.

Press AI and PR Spotlight are the next step in what Aquarius set out to do: put professional grade tools in the hands of the people who were never handed a team.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aquariusio-launches-press-ai–pr-spotlight-your-new-ai-team-302804726.html

SOURCE Aquarius.io

Continue Reading

Trending